Background: Globally, researchers have found that while the use of synthetic drugs worldwide has increased by 2.1 2.5%, the use of natural medicines has grown by 3.5-4.8%. In modern times, the pharmaceutical industry has become more advanced, and the use of plant-based medicines is increasing. As a result, there is a growing need to identify biologically active compounds in medicinal plants and produce domestic pharmaceutical products to replace imported medicines. Due to the limited research on evaluating the quality of the raw materials of the Asian globeflower(Тrollius asiaticus L.) this study serves as a basis for assessing the quality of that flowers Aim: Determining the quality parameters of flower of Trollius asiaticus L. Materials and Methods: The research work was carried out with the support of the “Quality Control Laboratory for Medicine” of the School of Pharmacy, MNUMS. The quality assessment of flower of Trollius asiaticus L. was conducted according to established parameters outlined in the National Pharmacopoeia of Mongolia and Russian pharmacopeia and Chinese pharmacopeia methods. Parameters such as appearance, and microbiological purity were evaluated. Statistical analysis of research data was performed using Microsoft Excel and SPSS 25 software to calculate the mean, standard deviation, and percentage. Results: The flower of Trollius asiaticus L. is orange red or orange, plant does not contain organic and mineral impurities, the quality analysis of flavonoid compounds by the thin layer chromatography, a spot with RF=0.5125 was detected at the same level as orientin as a standard substance, and a spot with RF=0.875 was detected at the same level as gallic acid as a standard substance when analyzing the quality of polyphenolic compounds, moisture contain is 5.52%, sulfated ash contain is 9.12%, acid insoluble ash contain is 3.39%, water soluble extract contained 36.21%, the total polyphenolic compound contained 5.37±0.22%, total flavonoid compound contained 0.0399±0.013%. Conclusion The quality parameters of flower of Trollius asiaticus L. have been determined by the Mongolia National of Pharmacopoeia, the Pharmacopoeia of Russian and China.

Background: In Mongolia, 80.1% of women of reproductive age suffer from vitamin D deficiency. This deficiency is associated with an increased risk of rickets, osteomalacia, weakened immunity, hypertension, diabetes, and infectious diseases.Currently, Mongolia imports vitamin D-containing pharmaceutical products, and no research has been conducted on the pharmaceutical formulation technology of orally administered vitamin D3 products. Vitamin D3 is highly sensitive to environmental factors such as ultraviolet (UV) light, oxidation, and temperature changes, leading to its degradation. Therefore, improving its stability in pharmaceutical formulations is essential. The need for a stable vitamin D3-containing pharmaceutical product serves as the basis for this study. Aim: To develop a tablet formulation containing cholecalciferol. Materials and Methods: The study was conducted in collaboration with the Department of Pharmaceutical Technology at the School of Pharmacy, Mongolian National University of Medical Sciences, and the drug development laboratory of “Monos Pharm” LLC. To enhance the stability and technological properties of cholecalciferol, a spray-drying technique was used to prepare five different emulsions containing various excipients. Microencapsulation was performed to improve stability, and the most suitable formulation and technological parameters were selected. From the microencapsulated cholecalciferol, tablet formulations were developed using both direct compression and wet granulation techniques. The quality parameters of the tablets were assessed according to the United States Pharmacopeia (USP), and the optimal technological process for tablet production was determined. Results: A stable microencapsulated cholecalciferol formulation was successfully developed, and suitable excipients were selected. The quantitative content of cholecalciferol was determined to be 1791 IU, with variations ranging from -8.38% to -11.38%. Conclusion The study identified appropriate excipients and technological parameters for obtaining microencapsulated cholecalciferol. Additionally, the optimal formulation and processing parameters for developing a tablet dosage form containing microencapsulated cholecalciferol were established.